Xanomeline-Trospium (Cobenfy) for Schizophrenia in Adults
Start Cobenfy at 50 mg/20 mg twice daily for at least 2 days, then increase to 100 mg/20 mg twice daily for at least 5 days, with a maximum dose of 125 mg/30 mg twice daily based on tolerability—but you must screen for contraindications and monitor liver enzymes and heart rate before and during treatment. 1
Dosing Schedule
The FDA-approved titration protocol is structured and non-negotiable 1:
- Days 1-2: 50 mg/20 mg orally twice daily
- Days 3-7: 100 mg/20 mg orally twice daily
- Day 8 onward: May increase to 125 mg/30 mg twice daily based on patient tolerability and response
- Maximum dose: 125 mg/30 mg twice daily
Critical administration requirements 1:
- Take at least 1 hour before meals OR at least 2 hours after meals
- Do not open capsules
- Twice daily dosing required
Geriatric Dosing Modifications
For elderly patients, start at 50 mg/20 mg twice daily with slower titration, and cap the maximum dose at 100 mg/20 mg twice daily 1. This reflects increased risk of urinary retention and anticholinergic effects in this population.
Absolute Contraindications
Cobenfy is contraindicated in patients with 1:
- Urinary retention (pre-existing)
- Moderate or severe hepatic impairment (Child-Pugh Class B or C)
- Gastric retention
- Hypersensitivity to xanomeline or trospium (angioedema reported)
- Untreated narrow-angle glaucoma
Required Pre-Treatment Assessment
Before initiating Cobenfy, you must 1:
- Assess liver enzymes (ALT/AST) and bilirubin - contraindicated if moderate-severe hepatic impairment
- Measure baseline heart rate - drug causes mean increase of 9.8 bpm over 24 hours
- Screen for urinary retention risk factors: benign prostatic hyperplasia, diabetic cystopathy, bladder outlet obstruction
- Assess renal function (eGFR) - not recommended if eGFR <60 mL/min due to trospium accumulation
Monitoring During Treatment
Liver Function
Check liver enzymes as clinically indicated during treatment 1. In clinical trials, 2.8% of patients developed ALT/AST elevations ≥3x upper limit of normal, typically within the first month 1. Most cases resolved with continued use (suggesting hepatic adaptation), but some required treatment interruption.
Cardiovascular Monitoring
Monitor heart rate, particularly in the first 2 weeks 1. Peak heart rate elevation occurs on Day 8 (mean increase 13.5 bpm vs 4.0 bpm placebo), partially attenuating by Week 5 (11.4 bpm vs 5.5 bpm placebo). Blood pressure monitoring is also warranted—11% developed hypertension vs 2% on placebo 1.
Urinary Function
Actively monitor for urinary retention symptoms: hesitancy, weak stream, incomplete emptying, dysuria 1. Risk is highest in males, elderly patients, and those with BPH. In long-term studies, 3.5% developed urinary retention, predominantly at maximum dose 1. If symptoms occur, reduce dose, discontinue, or refer for urologic evaluation.
Gastrointestinal Effects
The most common adverse effects are GI-related and typically mild-to-moderate 1, 2, 3:
- Nausea (19% vs 4% placebo)
- Dyspepsia (18% vs 5%)
- Constipation (17% vs 7%)
- Vomiting (15% vs 1%)
These effects generally resolve with continued treatment 2, 4. Consider implementing a constipation prevention protocol given the 17% incidence 4.
Populations Requiring Caution
Not Recommended
- Mild hepatic impairment - higher xanomeline exposure increases adverse reaction risk 1
- Moderate-severe renal impairment (eGFR <60) - trospium accumulation increases anticholinergic effects 1
Special Monitoring
- Elderly patients: Higher risk of urinary retention, anticholinergic CNS effects (dizziness, confusion, hallucinations, somnolence) 1
- Patients with biliary disease: Monitor for cholelithiasis and cholecystitis 1
Clinical Context
Cobenfy represents the first non-dopaminergic treatment for schizophrenia, acting as a muscarinic M1/M4 receptor agonist 5, 6. In phase 3 trials, it demonstrated a pooled effect size of 0.61 for PANSS total score reduction—larger than other agents approved since 1996 6. Critically, it causes no extrapyramidal symptoms, weight gain, or hyperprolactinemia 2, 3, 7, addressing major tolerability issues with traditional antipsychotics.
Long-term data show sustained efficacy: after 52 weeks, over 75% of patients achieved >30% PANSS improvement with mean score reduction of 33.3 points 2, 3. The 2025 INTEGRATE guidelines emphasize early treatment assessment and switching for inadequate response 8, making Cobenfy a viable first- or second-line option given its distinct mechanism and favorable metabolic profile.
Common Pitfalls
- Dosing with food: Reduces absorption—must dose 1 hour before or 2 hours after meals 1
- Missing contraindication screening: Particularly urinary retention and hepatic impairment
- Inadequate urinary monitoring in high-risk patients: Males, elderly, BPH patients need close surveillance
- Ignoring early GI symptoms: While usually self-limited, nausea/vomiting led to 2-3% discontinuation 1
- Exceeding geriatric dose limits: Maximum 100 mg/20 mg twice daily in elderly, not 125 mg/30 mg 1